Matignon Marie, Dahan Karine, Fruchaud Ghislaine, Audard Vincent, Grimbert Philippe, Lang Philippe
Service de néphrologie-transplantation, Hôpital Henri Mondor, Créteil.
Presse Med. 2007 Dec;36(12 Pt 2):1829-34. doi: 10.1016/j.lpm.2007.04.037. Epub 2007 Oct 24.
In France, kidney transplantation is part of - and is reimbursed as - treatment for chronic kidney disease. Long-term survival and quality of life are better for transplant recipients than for dialysis patients. Stagnation in the survival rate of transplants over the past 10 years has led to the development of new immunosuppressive drugs to minimize the use of corticosteroids and anticalcineurins and to induce tolerance of the transplanted kidney. The scarcity and lower quality of kidneys for transplantation is also leading to the development of new transplantation sources: donors with cardiac arrest and elderly, living and ABO-incompatible donors.
在法国，肾移植是慢性肾病治疗的一部分并可获得报销。肾移植受者的长期生存率和生活质量优于透析患者。过去10年肾移植存活率停滞不前，促使新型免疫抑制药物得以研发，以尽量减少皮质类固醇和抗钙调神经磷酸酶的使用，并诱导对移植肾的耐受性。用于移植的肾脏稀缺且质量较低，这也促使新型移植来源的出现：心脏骤停供者、老年供者、活体供者以及ABO血型不相容供者。
